The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women

By Westergaard Lars G.   Erb Karin   Laursen Steen   Rasmussen Per E.   Rex Sven  

Human Reproduction, Vol. 11, Iss. 6, 1996-06 ,pp. : 1209-1213

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization

By Sills E.Scott  

Human Reproduction, Vol. 14, Iss. 9, 1999-09 ,pp. : 2230-2235

Oxford University Press

Access to resources Recommend Favorite

The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization

By Devroey P  

Human Reproduction, Vol. 13, Iss. 3, 1998-03 ,pp. : 565-566

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study

By Tulppala Maija   Aho Milla   Tuuri Timo   Vilska Sirpa   Foudila Tuija   Hakala-Ala-Pietilä Tiina   Moilanen Jarna   Bützow Tarja   Kaukoranta Seija   Söderström-Anttila Viveca   Siegberg Rita   Suikkari Anne-Maria  

Human Reproduction, Vol. 14, Iss. 11, 1999-11 ,pp. : 2709-2715

Oxford University Press

Access to resources Recommend Favorite

A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon®) in women undergoing ovarian stimulation

By Out HJ  

Human Reproduction, Vol. 14, Iss. 3, 1999-03 ,pp. : 622-627

Oxford University Press

Access to resources Recommend Favorite